Showing 281 - 300 results of 6,657 for search 'significant ((((side decrease) OR (step decrease))) OR (((teer decrease) OR (we decrease))))', query time: 0.66s Refine Results
  1. 281
  2. 282
  3. 283

    Cesarean section. by Eva Rydahl (6260771)

    Published 2025
    Subjects:
  4. 284
  5. 285
  6. 286
  7. 287
  8. 288
  9. 289
  10. 290
  11. 291

    The RehaGait® system. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  12. 292

    Flow chart of included patients and dropouts. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  13. 293

    Dataset of the analyzed data. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  14. 294

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  20. 300

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”